Jiangsu Aidea Pharmaceutical Co Ltd Total Assets
Jiangsu Aidea Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Jiangsu Aidea Pharmaceutical Co Ltd (688488) holds total assets worth CN¥1.98 Billion CNY (≈ $289.01 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Jiangsu Aidea Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
Total assets of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025. This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 688488 stock price and chart for real-time trading data and today's change.
Jiangsu Aidea Pharmaceutical Co Ltd - Asset Composition Analysis
Jiangsu Aidea Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Jiangsu Aidea Pharmaceutical Co Ltd total assets breakdown as of December 2025. Jiangsu Aidea Pharmaceutical Co Ltd's total assets of CN¥1.98 Billion consist of 49.1% current assets and 50.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.4% |
| Accounts Receivable | CN¥151.41 Million | 7.9% |
| Inventory | CN¥259.49 Million | 13.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥190.18 Million | 9.9% |
| Goodwill | CN¥171.62 Million | 9.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Jiangsu Aidea Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Jiangsu Aidea Pharmaceutical Co Ltd short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Aidea Pharmaceutical Co Ltd's current assets represent 49.1% of total assets in 2025, an increase from 37.7% in 2016.
- Cash Position: Cash and equivalents constituted 19.4% of total assets in 2025, up from 7.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, a decrease from 18.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 13.6% of total assets.
Jiangsu Aidea Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Aidea Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
Jiangsu Aidea Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.63 | 1.40 | 12.63 |
| Quick Ratio | 1.18 | 1.01 | 10.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥385.42 Million | CN¥274.40 Million | CN¥807.89 Million |
Jiangsu Aidea Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Aidea Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.50 |
| Latest Market Cap to Assets Ratio | 0.38 |
| Asset Growth Rate (YoY) | 2.3% |
| Total Assets | CN¥1.91 Billion |
| Market Capitalization | $724.72 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Aidea Pharmaceutical Co Ltd's assets below their book value (0.38x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Jiangsu Aidea Pharmaceutical Co Ltd's assets grew by 2.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Jiangsu Aidea Pharmaceutical Co Ltd (2016–2025)
The table below shows the annual total assets of Jiangsu Aidea Pharmaceutical Co Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.91 Billion ≈ $279.87 Million |
+2.30% |
| 2024-12-31 | CN¥1.87 Billion ≈ $273.58 Million |
+7.04% |
| 2023-12-31 | CN¥1.75 Billion ≈ $255.58 Million |
+5.52% |
| 2022-12-31 | CN¥1.66 Billion ≈ $242.21 Million |
+15.38% |
| 2021-12-31 | CN¥1.43 Billion ≈ $209.93 Million |
-0.84% |
| 2020-12-31 | CN¥1.45 Billion ≈ $211.72 Million |
+85.26% |
| 2019-12-31 | CN¥780.98 Million ≈ $114.28 Million |
+10.16% |
| 2018-12-31 | CN¥708.95 Million ≈ $103.74 Million |
+7.54% |
| 2017-12-31 | CN¥659.24 Million ≈ $96.47 Million |
+48.63% |
| 2016-12-31 | CN¥443.55 Million ≈ $64.91 Million |
-- |
About Jiangsu Aidea Pharmaceutical Co Ltd
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules… Read more